Related Experiment Video
Updated: Jun 23, 2026

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
Carborane Hydrophobic Tags Drive Selective Degradation of Endogenous KRASG12C via HSP70-Ubiquitin-Proteasome Pathway
Yujie Shao1,2, Kazuki Miura1,2, Hiroyuki Nakamura1,2
1School of Life Science and Technology, Institute of Science Tokyo, 4259 Nagatsuta-cho Midori-ku, Yokohama 226-8501, Japan.
Abstract:
Persistent activation of the Kirsten rat sarcoma viral oncogene homologue (KRAS)G12C mutation sustains oncogenic signaling, and covalent inhibitors often yield incomplete pathway suppression or resistance. Herein, we developed hydrophobic-tag (HyT) degraders by introducing a carborane cluster into MRTX849, an KRASG12C covalent ligand, to promote selective elimination of endogenous KRASG12C. The carborane-HyT conjugates (HY8) reduced KRASG12C abundance and ERK phosphorylation in mutant cancer cells while showing lower intrinsic cytotoxicity and activity equal or superior to the adamantane-HyT analogue (HY5). Mechanistic studies indicate that HY8 acts in an E3 ligase-independent, chaperone-assisted pathway. KRAS degradation was rescued by the proteasome inhibitor MG132, but not by the lysosomal inhibitor bafilomycin A1, consistent with the increased level of KRAS ubiquitination and heat shock protein 70 engagement. Competition with MRTX849 blocked KRAS degradation, supporting on-target covalent engagement at Cys12. These findings establish carborane as a compact, functional HyT that drives proteasome-dependent degradation of endogenous KRASG12C and suppresses downstream signaling, broadening degrader design to include an E3-independent modality for the degradation of oncogenic proteins.
Insights
Researchers developed novel carborane-based degraders (HY8) that selectively eliminate Kirsten rat sarcoma viral oncogene homologue (KRAS)G12C. This approach offers a new strategy for targeting oncogenic KRAS proteins and suppressing cancer signaling pathways.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Persistent activation of KRASG12C mutations drives oncogenic signaling in various cancers.
- Existing covalent inhibitors for KRASG12C may lead to incomplete pathway suppression or drug resistance.
Purpose of the Study:
- To develop novel hydrophobic-tag (HyT) degraders for selective elimination of endogenous KRASG12C.
- To investigate the mechanism of action and efficacy of carborane-HyT conjugates (HY8) against KRASG12C.
Main Methods:
- Development of carborane-HyT conjugates (HY8) by incorporating a carborane cluster into an MRTX849 KRASG12C covalent ligand.
- Assessment of KRASG12C abundance, ERK phosphorylation, and cytotoxicity in mutant cancer cells.
- Mechanistic studies involving proteasome and lysosomal inhibitors, ubiquitination assays, and heat shock protein 70 engagement.
Main Results:
- Carborane-HyT conjugates (HY8) effectively reduced KRASG12C abundance and ERK phosphorylation.
- HY8 demonstrated lower intrinsic cytotoxicity compared to analogues, with equal or superior activity.
- Degradation occurred via an E3 ligase-independent, chaperone-assisted, proteasome-dependent pathway, confirmed by resistance to lysosomal inhibition and rescue by proteasome inhibition.
Conclusions:
- Carborane serves as a functional hydrophobic tag for driving proteasome-dependent degradation of endogenous KRASG12C.
- This study broadens degrader design strategies to include E3-independent modalities for targeting oncogenic proteins.
- The developed HY8 conjugates represent a promising therapeutic strategy for cancers driven by KRASG12C mutations.
Related Concept Videos
The Ras Gene
Ras is a superfamily...
Export of Misfolded Proteins out of the ER
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
GPCR Desensitization

